Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Lumigan Unsubstantiated Superiority Claims Cited In FDA Warning Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

The company must send corrective messages regarding the violative sales aid for Lumigan that contains misleading claims regarding the superiority of the ocular therapy, FDA says.
Advertisement

Related Content

Don't Be Inspired To Cite Non-Clinical Data Like Clinical Data In Drug Ads, DDMAC Says
Don't Be Inspired To Cite Non-Clinical Data Like Clinical Data In Drug Ads, DDMAC Says
FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit
FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit
Allergan Promo For Acular LS Broadens Indications, FDA Warning Letter Says
Allergan Promo For Acular LS Broadens Indications, FDA Warning Letter Says
Alcon’s Travatan Ad Comparisons To Xalatan, Lumigan Are Misleading, FDA Says
Alcon’s Travatan Ad Comparisons To Xalatan, Lumigan Are Misleading, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS062998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel